Product Name: Canertinib dihydrochloride
Synonyms: Canertinib Dihydrochloride (CI-1033 HCl);Canertinib (CI-1033) HCl;CANERTINIB DIHYDROCHLORIDE;N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride;Canertinib dihydrochloride (CI-1033;Canertinib.2HCL;CI-1033;N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride
CAS: 289499-45-2
MF: C24H27Cl3FN5O3
MW: 558.86
EINECS:
Product Categories: API;Inhibitors
Mol File: 289499-45-2.mol

Canertinib dihydrochloride Chemical Properties
storage temp.  20°C
solubility  DMSO: >10mg/mL
form  solid
Safety Information
Hazard Codes  Xi
Risk Statements  36/37/38
Safety Statements  26
WGK Germany  3
RTECS  UC6316110

Canertinib dihydrochloride Usage And Synthesis
Uses CI-1033 is a potent inhibitor of EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, respectively.
Uses The HER family of receptor tyrosine kinases, EGFR, HER2, HER3, and HER4, mediate proliferation, migration, adhesion, differentiation, and survival in many different cell types and have been implicated in the development and progression of a variety of human tumors.Canertinib dihydrochloride is an irreversible quinazoline-based HER family tyrosine kinase inhibitor with IC50 values of 0.8, 19, and 7 nM for blocking in vitro activity of EGFR, HER2, and HER4, respectively. As a broadly applicable anti-cancer agent, it has been used to suppress proliferation of malignant peripheral nerve sheath tumor cells (effective concentration of 250-500 nM), to inhibit growth and induce dose-dependent apoptosis in a panel of neuroblastoma cell lines (IC50s = 0.94-2.45 μM), and to reduce proliferation of acute myeloid leukemia cells (IC50 = 0.27 μM). Canertinib dihydrochloride also displays anti-neoplastic activity towards T98G glioblastoma cells, HCT8 colorectal carcinoma cells, and cells expressing the breast cancer resistance protein.

Product Name: Canertinib dihydrochloride
Synonyms: Canertinib Dihydrochloride (CI-1033 HCl);Canertinib (CI-1033) HCl;CANERTINIB DIHYDROCHLORIDE;N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride;Canertinib dihydrochloride (CI-1033;Canertinib.2HCL;CI-1033;N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride
CAS: 289499-45-2
MF: C24H27Cl3FN5O3
MW: 558.86
EINECS:
Product Categories: API;Inhibitors
Mol File: 289499-45-2.mol

Canertinib dihydrochloride Chemical Properties
storage temp.  20°C
solubility  DMSO: >10mg/mL
form  solid
Safety Information
Hazard Codes  Xi
Risk Statements  36/37/38
Safety Statements  26
WGK Germany  3
RTECS  UC6316110

Canertinib dihydrochloride Usage And Synthesis
Uses CI-1033 is a potent inhibitor of EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, respectively.
Uses The HER family of receptor tyrosine kinases, EGFR, HER2, HER3, and HER4, mediate proliferation, migration, adhesion, differentiation, and survival in many different cell types and have been implicated in the development and progression of a variety of human tumors.Canertinib dihydrochloride is an irreversible quinazoline-based HER family tyrosine kinase inhibitor with IC50 values of 0.8, 19, and 7 nM for blocking in vitro activity of EGFR, HER2, and HER4, respectively. As a broadly applicable anti-cancer agent, it has been used to suppress proliferation of malignant peripheral nerve sheath tumor cells (effective concentration of 250-500 nM), to inhibit growth and induce dose-dependent apoptosis in a panel of neuroblastoma cell lines (IC50s = 0.94-2.45 μM), and to reduce proliferation of acute myeloid leukemia cells (IC50 = 0.27 μM). Canertinib dihydrochloride also displays anti-neoplastic activity towards T98G glioblastoma cells, HCT8 colorectal carcinoma cells, and cells expressing the breast cancer resistance protein.